Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | HRAS | P01112 | 2/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6659183 | 1.00 | SLC6A2 (0.51) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL969972 | 1.00 | SLC6A2 (0.51) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL630301 | 1.00 | SLC6A2 (0.51) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL8960128 | 0.95 | SLC6A2 (0.52) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL8960525 | 0.95 | SLC6A2 (0.52) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL8960125 | 0.95 | SLC6A2 (0.52) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL8960350 | 0.95 | SLC6A2 (0.52) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL8960222 | 0.95 | SLC6A2 (0.52) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL8960215 | 0.95 | SLC6A2 (0.52) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL6552387 | 0.92 | SLC6A2 (0.50) | SLC6A2PDE4DTSHRCYP2C19TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0730601-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | UNIV WASHINGTON (US) | 2004-07-14 | — | — | EP | claimed |
| US-9149489-B2 | Inhibitors of glycolysis useful in the treatment of brain tumors | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2015-10-06 | — | — | US | disclosed |
| US-20110003758-A1 | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-06 | — | — | US | disclosed |
| WO-2009108926-A1 | INHIBITORS OF GLYCOLYSIS USEFUL IN THE TREATMENT OF BRAIN TUMORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-09-03 | — | — | WO | disclosed |
| US-5491152-A | Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| WO-1995014028-A9 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | — | 1995-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003758-A1 | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors | PDK2, G6PD, PCK2 | SLC6A2 1422/4885PDE4D 2963/4885TSHR 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.